Form D · Biotechnology

Stemgenics, Inc.

Seattle, WA · CIK 0001595336

Offering snapshot reported Jul 20, 2018 · SEC filing

Reported sold
$445K
Offering amount: $20M
Investors reported
8
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 20, 2018
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 20, 2018Initial$445,000No comparison8SEC filing
Jan 11, 2018Amendment$1,800,000$870,000vs Jan 14, 201639SEC filing
Jan 14, 2016Initial$930,000No comparison17SEC filing
Jan 3, 2014Initial$1,100,000No comparison13SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-317421
Minimum sales milestones triggering finders' fees were not met by June deadline, so no fees paid or owing thus far.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Frederick S. HagenNone
Endeavor Capital Management HoldingsNone

Source: Form D, filed Jul 20, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Andranik Aprikyan Director, Executive
Frederick S Hagen Director, Executive
Mushegh Hovhannisyan Director, Executive
Anush Oganesian Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
454 N. 34 Th Street Suite 100
Seattle, WA, 98103